Chemoradiation, Glioblastoma Multiforme
Conditions
Keywords
Glioblastoma, Chemoradiation, Simultaneous integrated boost
Brief summary
Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme. The aim of this study was to investigate the value of chemoradiation (CCRT) using SIB in glioblastoma and the correlation with surgical extent.
Detailed description
The SIB technique provides the higher radiobiological effect with the same fractionation scheme, i.e. 69 Gy over 6 weeks, which might increase the loco-regional control. Besides, the co-registration with magnetic resonance imaging (MRI) strengthens the precision of target delineation as well as higher possibility to spare adjacent normal brain tissue. In this protocol, the newly diagnosed, primary glioblastoma patients received SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. To determine the status of surgical extent, postoperative CT scan and MRI was acquired within 72 hours and at 4th week after surgery. During the period of chemoradiation, acute neurotoxicity and hematological toxicity was assessed as well.
Interventions
RADIATIONSimultaneous integrated boost
Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
Sponsors
Taichung Veterans General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A prospectively single arm in single institution.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* age 18 years or above * newly diagnosed, tissue-proven glioblastoma * pre-radiotherapy Karnofsky performance score (KPS) ≧60.
Exclusion criteria
* any previous history of chemotherapy or radiotherapy * receiver of any investigating agents * recurrent GBM * any second malignancies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free survival rate | at the end of first year | Actual one-year progression-free survival rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Surgical extent | CT within 72 hours and MRI at 4th week after surgery | No contrast-enhanced area: gross total resection; Any contrast-enhanced area: residual tumor |
Countries
Taiwan
Outcome results
None listed